Computing and Library Services - delivering an inspiring information environment

Short- and long-term efficacy and safety of risperidone in adults with disruptive behavior disorders

Gagiano, Carllo, Read, Stephen, Thorpe, Lilian, Eerdekens, Marielle and Van Hove, Ilse (2005) Short- and long-term efficacy and safety of risperidone in adults with disruptive behavior disorders. Psychopharmacology, 179 (3). pp. 629-636. ISSN 1432-2072

Metadata only available from this repository.


Rationale Function in society can be severely affected by disruptive behaviors in adults.
Objectives To examine the efficacy and safety of risperidone in the treatment of disruptive behavior disorders in intellectually disabled adults.
Methods Intellectually disabled patients with disruptive behavior disorder were randomly assigned to receive risperidone (n=39) in a flexible dosage ranging from 1 to 4 mg/day (mean dosage, 1.45±0.08 mg/day) or placebo (n=38) for 4 weeks of double-blind treatment. Efficacy at endpoint was measured primarily by using the Aberrant Behavior Checklist (ABC); secondary efficacy measures included the Behavior Problems Inventory and Clinical Global Impressions scales. After this 4-week period, patients could enter open-label treatment with risperidone for 48 weeks.
Results Risperidone was well tolerated, and patients treated with risperidone demonstrated significantly greater improvement at endpoint on the ABC than those who received placebo [–27.3 points (52.8% improvement) versus –14.9 points (31.3% improvement); P=0.036] and also improved on Behavior Problems Inventory and Clinical Global Impressions ratings. Over the 48-week, open-label follow-up period, there was a further decrease of 6.3 points (P0.05) on the ABC for patients who initially received risperidone and a decrease of 11.3 points (P0.05) for patients who initially received placebo and were switched to open-label risperidone. These results were achieved with a mean modal dosage of 1.8 mg/day.
Conclusion Risperidone is efficacious and well tolerated in managing disruptive behavior disorders in adults with intellectual disability

Item Type: Article
Subjects: R Medicine > R Medicine (General)
R Medicine > RC Internal medicine > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry
Schools: School of Human and Health Sciences
Related URLs:

Allison DB, Casey DE (2001) Antipsychotic-induced weight gain: a
review of the literature. J Clin Psychiatry 62(Suppl 7):22–31
Aman MG, Singh NN, Stewart AW, Field CJ (1985) The aberrant
behavior checklist: a behavior rating scale for the assessment of
treatment effects. Am J Ment Defic 89:485–491
Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL, and the
Risperidone Disruptive Behavior Study Group (2002) Doubleblind,
placebo-controlled study of risperidone for the treatment
of disruptive behaviors in children with subaverage intelligence.
Am J Psychiatry 159:1337–1346
Brar JS, Ganguli, R, Pandina, G, Turkoz I, Berry S, Mahmoud R (in
press) Effects of behavioral therapy on weight loss in overweight
and obese patients with schizophrenia or schizoaffective
disorder. J Clin Psychiatry
Buitelaar JK (2000) Open-label treatment with risperidone of 26
psychiatrically-hospitalized children and adolescents with mixed
diagnosis and aggressive behavior. J Child Adolesc Psychopharmacol
Chouinard G, Ross-Canard A, Annable L, Jones BD (1980) The
extrapyramidal symptom rating scale [abstract]. Can J Neurol
Sci 7:233
Cohen SA, Ihrig K, Lott RS, Kerrick JM (1998) Risperidone for
aggression and self-injurious behavior in adults with mental
retardation. J Autism Dev Disord 28:229–233
Csernansky JG, Mahmoud R, Brenner R (2002) A comparison of
risperidone and haloperidol for the prevention of relapse in
patients with schizophrenia. N Engl J Med 346:16–22
Dartnall NA, Holmes JP, Morgan SN, McDougle CJ (1999) Brief
report: two-year control of behavioral symptoms with risperidone
in two profoundly retarded adults with autism. J Autism
Dev Disord 29:87–91
Emerson E, Kiernan C, Alborz A, Reeves D, Mason H, Swarbrick
R, Mason L, Hatton C (2001) The prevalence of challenging
behaviors: a total population study. Res Dev Disabil 22:77–93
Farrington DP, Gallagher B, Morley L, St Ledger RJ,West DJ (1988)
Are there any successful men from criminogenic backgrounds?
Psychiatry 51:116–130
Fergussen DM, Horwood LJ (1998) Early conduct problems and
later life opportunities. J Child Psychol Psychiatry 39:1097–
Findling RL, Maxwell K, Wiznitzer M (1997) An open clinical trial
of risperidone monotherapy in young children with autistic
disorder. Psychopharmacol Bull 33:155–159
Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon
E, Blumer JL (2000) A double-blind pilot study of risperidone
in the treatment of conduct disorder. J Am Acad Child Adolesc
Psych 39:509–516
Guy W (1976) Clinical global impressions. In: ECDEU assessment
manual for psychopharmacology, revised 1976. National Institute
of Mental Health, Rockville, MD, pp 217–222
McDougle CJ, Brodkin ES, Yeung PP, Naylor ST, Cohen DJ, Price
LH (1995) Risperidone in adults with autism or pervasive
developmental disorder. J Child Adolesc Psychopharmacol 5:
635McDougle CJ, Holmes JP, Bronson MR, Anderson GM, Volkmar FR,
Price LH, Cohen DJ (1997) Risperidone treatment of children
and adolescents with pervasive developmental disorders: a
prospective, open-label study. J Am Acad Child Adolesc Psych
Nicolson R, Awad G, Sloman L (1998) An open trial of risperidone
in young autistic children. J Am Acad Child Adolesc Psych
Purdon SE, Lit W, Labelle A, Jones BD (1994) Risperidone in the
treatment of pervasive developmental disorder. Can J Psychiatry
Robins LN (1966) Deviant children grow up: a sociological and
psychiatric study of sociopathic personality. Williams &
Wilkins, Baltimore, MD
Rojahn J (1992) Behavior problems inventory: a prospectus.
Nisonger Center for Mental Retardation and Developmental
Disabilities, Ohio State University
Santosh PJ, Baird G (1999) Psychopharmacotherapy in children and
adults with intellectual disability. Lancet 354:233–242
Simon EW, Blubaugh KM, Pippidis M (1996) Substituting
traditional antipsychotics with risperidone for individuals with
mental retardation. Ment Retard 34:359–366
Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A, and
the Risperidone Conduct Study Group (2002) Effects of risperidone
on conduct and disruptive behavior disorders in children
with subaverage IQs. J Am Acad Child Adolesc Psych 41:
Swann AC (2003) Neuroreceptor mechanisms of aggression and its
treatment. J Clin Psychiatry 64(Suppl 4):26–35
Turgay A, Binder C, Snyder R, Fisman S (2002) Long-term safety
and efficacy of risperidone for the treatment of disruptive behavior
disorders in children with subaverage IQs. Pediatrics 110:
Van Bellinghen M, De Troch C (2001) Risperidone in the treatment
of behavioral disturbances in children and adolescents with
borderline intellectual functioning: a double-blind, placebocontrolled
pilot trial. J Child Adolesc Psychopharmacol 11:5–
Van Elteren PH (1960) On the combination of independent twosample
tests of Wilcoxon. Bull Int Stat Inst 37:351–361
Vanden Borre R, Vermote R, Buttiens M, Thiry P, Dierick G,
Geutjens J, Sieben G, Heylen S (1993). Risperidone as add-on
therapy in behavioral disturbances in mental retardation: a
double-blind placebo-controlled cross-over study. Acta Psychiatr
Scand 87:167–171
Werneke U, Taylor D, Sanders TAB (2002) Options for pharmacological
management of obesity in patients treated with
atypical antipsychotics. Int Clin Psychopharmacol 17:145–160
Zarcone JR, Hellings JA, Crandall K, Reese RM, Marquis J,
Fleming K, Shores R, Williams D, Schroeder SR (2001) Effects
of risperidone on aberrant behavior of persons with developmental
disabilities: a double-blind crossover study using multiple
measures. Am J Ment Retard 106:525–538

Depositing User: Sara Taylor
Date Deposited: 17 Apr 2008 15:51
Last Modified: 30 Oct 2008 14:40


Downloads per month over past year

Repository Staff Only: item control page

View Item View Item

University of Huddersfield, Queensgate, Huddersfield, HD1 3DH Copyright and Disclaimer All rights reserved ©